Answers are grounded in this paper and cite their sources.
VEB-1 extended-spectrum β-lactamase-producing Acinetobacter baumannii was responsible for an outbreak in hospitals in France.A national alert was triggered in September 2003 when 4 hospitals reported clusters of A. baumannii infection with similar susceptibility profiles.Case definitions and laboratory guidelines were disseminated, and prospective surveillance was implemented; strains were sent to a single laboratory for characterization and typing.From April 2003through June 2004, 53 hospitals reported 290 cases of A. baumannii infection or colonization; 275 isolates were bla VEB-1 -positive and clonally related.Cases were first reported in 5 districts of northern France, then in 10 other districts in 4 regions.Within a region, interhospital spread was associated with patient transfer.In northern France, investigation and control measures led to a reduction of reported cases after January 2004.The national alert enabled early control of new clusters, demonstrating the usefulness of early warning about antimicrobial drug resistance.D uring the past decade, nosocomial outbreaks of Acinetobacter baumannii have been described with increasing frequency, occurring mostly in intensive care units, burn units, and surgical wards (1,2).Epidemic strains of A. baumannii are often resistant to several antimicrobial drugs, which reduces treatment effective-ness.Nosocomial transmission is from patient to patient and associated with environmental reservoirs (2).Several risk factors for A. baumannii infections have been identified and include severity of underlying disease, duration of hospitalization, invasive procedures, and prior broad-spectrum antimicrobial drug therapy (2-4).A. baumannii can be detected in patients without infection (i.e., colonization) or as the source in patients with severe infections; the casefatality ratio varies from 17% to 46% for septicemia and can be as high as 70% for pneumonia (1).A. baumannii is not the most common antimicrobial drug-resistant pathogen in hospitalized patients; it accounted for 1.2% of all nosocomial infections in 2001 in France (5).However, increasing therapeutic difficulty caused by resistance is a serious concern (6-9).A variety of molecular mechanisms for resistance to broad-spectrum β-lactams have been reported in A. baumannii, such as mutations of penicillin-binding proteins and alterations of membrane permeability, but the most common mechanism is attributed to the presence of β-lactamases encoded by either chromosomes or plasmids (2,10,11).Several class A, B, and D β-lactamases (2,8) as well as chromosome-mediated cephalosporinases (12) confer various resistance phenotypes.Moreover, extended-spectrum β-lactamase (ESBL)-producing A. baumannii strains have also been described: PER-1 in Turkey, Korea, and France (13-15); VEB-1 in France (4,16); and CTX-M-2 recently in Japan (17).
No takes yet. Share an insight, caveat, or question.
Naas et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: